|
Market Closed -
Australian S.E.
14:10:10 14/08/2026 HKT
|
5-day change | 1st Jan Change | ||
| 9.550 AUD | -0.42% |
|
+1.17% | -23.35% |
| Market Cap | 482M 341M 295M 277M 252M 474M 32.65B 3.25B 1.27B 16.35B 1.28B 1.25B 54.33B | P/E 2026 * |
13.5x | P/E 2027 * | 12.8x |
|---|---|---|---|---|---|
| Enterprise Value | 229M 162M 140M 132M 120M 225M 15.52B 1.54B 603M 7.77B 609M 596M 25.82B | EV / Sales 2026 * |
2.31x | EV / Sales 2027 * | 1.88x |
| Free-Float |
83.79% | Yield 2026 * |
0.64% | Yield 2027 * | 0.84% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | -0.42% | ||
| 1 week | +1.17% | ||
| Current month | +5.41% | ||
| 1 month | -4.31% | ||
| 3 months | +0.84% | ||
| 6 months | -9.91% | ||
| Current year | -23.35% |
| 1 week | 9.4 |  | 9.76 |
| 1 month | 8.77 | | 10.42 |
| Current year | 8.35 | | 13.48 |
| 1 year | 8.35 | | 14 |
| 3 years | 8.35 | | 21.45 |
| 5 years | 8.35 | | 44.67 |
| 10 years | 4.95 | | 45.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 01/11/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 30/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 29/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 23/09/2019 |
| Chairman | - | 01/01/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 3/10/24 | Buy | Director | 8,333 | 0.0166% | ||
| 27/11/23 | Fiscal year | Chief Executive Officer | 301,125 | 0.6094% | ||
| 27/11/23 | Expiration | Chief Executive Officer | 1,513,750 | 3.0636% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.42% | +1.17% | -22.42% | -53.00% | 341M | |
| -0.31% | +2.44% | +38.43% | -0.30% | 80.23B | |
| -1.02% | -0.51% | -2.54% | +26.80% | 50.64B | |
| -3.10% | -4.84% | +10.29% | +158.34% | 46.87B | |
| -0.74% | +3.26% | -49.51% | -49.96% | 46.34B | |
| -0.39% | +0.91% | +51.39% | -22.35% | 31B | |
| -0.52% | +7.01% | +125.98% | -34.32% | 25.28B | |
| -0.30% | -0.33% | +38.24% | +83.70% | 24.36B | |
| -1.42% | -1.11% | -3.79% | +190.40% | 20.81B | |
| -1.83% | -2.82% | +60.85% | +107.54% | 16.08B | |
| Average | -1.00% | +1.53% | +24.69% | +40.68% | 34.2B | |
| Weighted average by Cap. | -1.02% | +1.13% | +22.65% | +36.82% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 99.21M 70.33M 60.74M 57.08M 51.91M 97.6M 6.72B 669M 261M 3.37B 264M 258M 11.19B | 105M 74.15M 64.05M 60.18M 54.73M 103M 7.09B 705M 276M 3.55B 278M 272M 11.8B |
| Net income | 35.72M 25.32M 21.87M 20.55M 18.69M 35.14M 2.42B 241M 94.15M 1.21B 95.07M 93.01M 4.03B | 37.66M 26.7M 23.06M 21.67M 19.71M 37.05M 2.55B 254M 99.27M 1.28B 100M 98.06M 4.25B |
| Net Debt | -253M -179M -155M -145M -132M -249M -17.13B -1.7B -666M -8.58B -673M -658M -28.51B | -285M -202M -174M -164M -149M -280M -19.29B -1.92B -750M -9.66B -757M -741M -32.11B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/08/26 | A$9.550 | -0.42% | 52,527 |
| 13/08/26 | A$9.590 | +0.95% | 78,621 |
| 12/08/26 | A$9.500 | -2.16% | 93,054 |
| 11/08/26 | A$9.710 | +0.94% | 55,054 |
| 10/08/26 | A$9.620 | +1.91% | 66,738 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
Select your edition
All financial news and data tailored to specific country editions
